Short‐term outcome after high‐intensity focused ultrasound in the treatment of patients with high‐risk prostate cancer
Open Access
- 7 November 2006
- journal article
- Published by Wiley in BJU International
- Vol. 98 (6) , 1193-1198
Abstract
OBJECTIVE: To assess the short‐term outcome in patients with high‐risk prostate cancer treated by transrectal high‐intensity focused ultrasound (HIFU). PATIENTS AND METHODS: From April 2003 to November 2004, 30 patients with high‐risk prostate cancer were enrolled in this prospective study; all had transurethral resection of the prostate before transrectal HIFU treatment, using the Ablatherm device (EDAP, Lyon, France) during the same session, associated with hormonal therapy with luteinizing hormone‐releasing hormone analogues. After the procedure, all the patients were evaluated every 3 months by physical examination, prostate‐specific antigen (PSA) assay and a continence questionnaire. The follow‐up schedule also included a transperineal prostate biopsy 6 months after the treatment. All the patients had a minimum follow‐up of 12 months. RESULTS: The HIFU treatment took a median (interquartile range, IQR) of 140 (100–160) min. No complications were reported during treatment. The mean (IQR) hospitalization was 2.2 (1–4) days, and the suprapubic drainage tube was removed after 12 (7–18) days. The complications after treatment were: urinary tract infections in five patients (16%), stenosis of the intraprostatic and membranous urethra in three (10%), and secondary infravesical obstruction in four (13%). At 12 months after the procedure, 28 patients (93%) were continent. Seven of the 30 men (23%) had a positive prostate biopsy. At the 1‐year follow‐up only three of the 30 patients with high‐risk prostate cancer had a PSA level of >0.3 ng/mL. CONCLUSIONS: HIFU is a modern, minimally invasive therapy for prostate cancer, often used in selected patients with localized disease. The present results show that HIFU was also feasible in patients with high‐risk prostate cancer. The low complication rates and favourable functional outcome support the planning of further larger studies in such patients. The oncological efficacy of HIFU should be assessed in further studies with a longer follow‐up.Keywords
This publication has 25 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerBJU International, 2006
- The Potential Impact of Prostate Volume in the Planning of Optimal Number of Cores in the Systematic Transperineal Prostate BiopsyEuropean Urology, 2005
- EAU Guidelines on Prostate CancerEuropean Urology, 2005
- Technology Insight: high-intensity focused ultrasound for urologic cancersNature Reviews Endocrinology, 2005
- Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonographyUrology, 2004
- Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02Journal of Clinical Oncology, 2003
- Results and Side Effects of High-Intensity Focused Ultrasound in Localized Prostate CancerJournal of Endourology, 2001
- LOCAL CONTROL OF PROSTATE CANCER BY TRANSRECTAL HIGH INTENSITY FOCUSED ULTRASOUND THERAPYJournal of Urology, 1999
- Prostatic Tissue Destruction by High-Intensity Focused Ultrasound: Experimentation on Canine Prostate 1Journal of Endourology, 1993